Adults July 9-14 and 1, 010 Canadians on June 5-7. They aren’t scientific random samples, don’t statistically mirror the population and thus have no margin of mistake. This article is republished with kind authorization from our close friends at The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Plan Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J.announced the U.S. Food and Medication Administration has authorized updated safety information, including an updated boxed caution in the labeling info for the class of drugs referred to as erythropoiesis-stimulating brokers , including Aranesp and EPOGEN . The updated boxed warning claims that ESAs shortened general survival and/or time-to-tumor progression in scientific studies in sufferers with breast, non-small cell lung, head and neck, lymphoid and cervical cancers, when dosed to target a hemoglobin of greater than or equal to 12 g/dL. In the ‘Increased Mortality and/or Tumor Progression’ warning section of the up to date labeling, the interim results of the Preoperative Epirubicin Paclitaxel Aranesp study in neo-adjuvant breast cancers were added as well as follow-up data from the Gynecologic Oncology Group study in cervical cancers.